Qvest to Accelerate Generative AI for Media and Entertainment Businesses in Collaboration with NVIDIA
10.9.2024 16:03:00 EEST | Business Wire | Press release
IBC2024 -- Qvest, a leading consultant and systems integrator in media-focused services, today announced a collaboration with NVIDIA to drive AI adoption in the media and entertainment industry. These solutions powered by generative AI (GenAI), will create new opportunities for revenue generation, customer engagement, and operational efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910864873/en/
Christophe Ponsart - EVP and Applied AI Practice Co-Lead, Qvest US. (Photo: Business Wire)
Qvest is expanding its alliance program in artificial intelligence to further position the company as a leader in AI for media businesses. By fostering collaboration across industries and leveraging shared expertise, Qvest delivers tangible GenAI applications that drive ROI.
The collaboration with NVIDIA combines Qvest’s deep expertise in media and entertainment with NVIDIA’s leading AI capabilities and technology platform. This will deliver advanced AI-driven solutions that empower companies to harness the full potential of GenAI.
Using NVIDIA's AI technologies, Qvest is further developing GenAI offerings in its Applied AI practice that address the key business challenges of media companies and help increase their productivity, promote creativity and optimize processes.
“The collaboration with NVIDIA enables us to quickly deliver powerful use cases for media and entertainment companies. Together, we are helping our customers generate value from AI in areas most impactful for their business,” said Christophe Ponsart, EVP and Applied AI Practice Co-Lead, Qvest US.
A GenAI solution will be unveiled at the IBC Show in Amsterdam, streamlining content management and creation within existing media workflows for:
- Automated Metadata Tagging: Drastically reduces time and costs associated with manual cataloging by automating structured metadata tagging across multiple modalities (text, audio, vision).
- Accelerated Content Discovery: User enablement to quickly find relevant content across and within video assets.
- Empowered Content Generation: Generation and iteration on contextually relevant headlines, scripts, and narratives in seconds to accelerate time to market.
“Media and entertainment companies are looking to accelerate AI adoption to deliver enhanced experiences. By combining NVIDIA’s AI platform with Qvest’s industry expertise, Qvest is empowering customers to quickly move from idea to scalable implementation using the latest developments in AI,” said Richard Kerris, Vice President of Media and Entertainment at NVIDIA.
NVIDIA NIM inference microservices play a critical role in this collaboration, offering seamless hosting of state-of-the-art GenAI models for computer vision, content generation, audio transcription, and more. Companies can choose where to run their models, whether in the cloud or hosted locally, helping ensure that data remains secure while optimizing performance.
Qvest is committed to continuing its collaboration with NVIDIA, with plans to integrate NVIDIAHoloscan for Media, an AI-enabled, software-defined platform for live media, for real-time streaming ingestion and content discovery. This integration will help further enhance the capabilities of GenAI infrastructure, increasing security, reducing costs, boosting performance, and minimizing operational overhead.
Qvest’s GenAI accelerators, developed in collaboration with NVIDIA, will be showcased at IBC 2024, where attendees can experience a full range of tangible and practical GenAI use cases firsthand at Qvest’s booth (#10.C24). More about Qvest at IBC2024 at www.qvest.com/ibc2024
About Qvest
Qvest is a global leader in media-focused practices and services. Qvest supports companies holistically in their Digital Transformation with innovation, consulting and technology implementation services to achieve future-oriented change. With deep expertise in media, information and communications technology, Qvest supports its customers in transforming their business towards digitalization, cloud and AI. Qvest's customers include numerous global brands from industries such as media & entertainment, telecommunications, automotive, health & pharmaceuticals, consumer goods, retail, transportation, and logistics, as well as organizations from the public sector. In addition to its headquarters in Germany, the company operates locations across Europe, the USA, the Middle East, Southeast Asia, and Australia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910864873/en/
Contacts
Qvest Group GmbH
Christian Felder
Tel.: +49 174 9481 983
E-Mail: christian.felder@qvest.com
Web: www.qvest.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qvest.com&e
sheet=54119793&newsitemid=20240910864873&lan=en-US&anchor=www.qvest.com&index=3&
md5=c0a5bdcc8dfc89ea26ad0ef9f0362b7d
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom